Hoth Therapeutics, Inc

New York,  NY 
United States
https://ir.hoththerapeutics.com/index.php

• Booth: 2106a

Hoth Therapeutics is addressing some of today’s most pressing healthcare challenges with the next generation of therapeutics. Patients are at the forefront of our development strategy with a focus on identifying and solving unmet needs in various disease areas. Our purpose is to launch scientifically advanced products and ensure accessibility in order to deliver value to patients as well as all stakeholders across the healthcare continuum.

 Press Releases

• HT-001 for the treatment of cutaneous toxicities associated with EGFR inhibitor therapy (May 18, 2021)

  https://hoththerapeutics.com/wp-content/uploads/2021/05/HOTH-HT-001_Non-Confidential_MAY2021-1.pdf

• HT-KIT for the treatment of cancers resulting from aberrant KIT signaling (May 18, 2021)

  https://hoththerapeutics.com/wp-content/uploads/2021/05/HT-KIT-Presenation-ASCO-2021-1.pdf

• Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers (May 18, 2021)
  https://ir.hoththerapeutics.com/2021-05-03-Hoth-Therapeutics-Announces-Development-of-HT-KIT-to-Treat-Multiple-Orphan-Diseases,-Including-Rare-Cancers

• Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers (May 18, 2021)
  https://ir.hoththerapeutics.com/2021-04-20-Hoth-Therapeutics-Announces-its-mRNA-Frame-Shifting-Therapeutic-Significantly-Inhibits-Tumor-Growth-in-Mast-Cell-Derived-Cancers

• Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients (May 18, 2021)
  https://ir.hoththerapeutics.com/2021-02-23-Hoth-Therapeutics-Announces-Successful-Completion-of-Pre-IND-Meeting-with-FDA-Regarding-Proposed-Development-of-HT-001-For-Cancer-Patients